UNASSIGNED: Colony-stimulating factors (CSF) have been widely used to prevent @entity1398 associated with chemotherapy. Due to the high intensity of chemotherapy in @entity981 ( @entity981 ), CSF as a crucial component of supportive care has played a significant role in the therapy. However, the effectiveness of CSF in treatment has not been identified by large clinical trials until now. The aim of the present study was to evaluate the effect of CSF on the long-term outcome of @entity981 @entity1 . A comprehensive search strategy has been conducted, which covered the Cochrane Central Register of Controlled Trials, PubMed and Web of Science. The result includes seven randomized controlled trials containing a total of 753 @entity1 . The administration of CSF significantly reduced the mortality at the end of the follow-up (RR, 0.85; 95% CI, 0.75-0.95), the mortality at day 30 (RR, 0.41; 95% CI, 0.23-0.74) and the number of @entity1 with @entity281 or severe @entity281 (RR, 0.8; 95% CI, 0.7-0.9 and RR, 0.48; 95% CI, 0.3-0.75). The addition of CSF also marginally increased the number of @entity1 achieving CR (RR, 1.14; 95% CI, 1.05-1.23). The use of CSF also shortened the duration of @entity1398 (median days, 8-17 to 12.5-24). In conclusion, CSFs can be administered to @entity981 @entity1 during myelosuppressive chemotherapy, particularly in the induction phase.

Colony-stimulating factors for chemotherapy-related @entity1398 are associated with improved prognosis in adult XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'infections'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia'] @entity981 :: ('MESH:D054198', 'Disease') :: ['adult ALL', 'ALL', 'acute lymphoblastic leukemia']
@entity981 :: (MESH:D054198,Disease) :: ['acute lymphoblastic leukemia']
